Type III CRISPR-Cas provides resistance against nucleus-forming jumbo phages via abortive infection
D. Mayo-Munoz, L. M. Smith, C. Garcia-Doval, L. M. Malone, K. R. Harding, S. A. Jackson, H. G. Hampton, R. D. Fagerlund, L. F. Gumy, P. C. Fineran
Abstract
Bacteria have diverse defences against phages. In response, jumbo phages evade multiple DNA-targeting defences by protecting their DNA inside a nucleus-like structure. We previously demonstrated that RNA-targeting type III CRISPR-Cas systems provide jumbo phage immunity by recognising viral mRNA exported from the nucleus for translation. Here, we demonstrate that recognition of phage mRNA by the type III system activates a cyclic triadenylate-dependent accessory nuclease, NucC. Although unable to access phage DNA in the nucleus, NucC degrades the bacterial chromosome, triggers cell death, and disrupts phage replication and maturation. Hence, type III-mediated jumbo phage immunity occurs via abortive infection, with suppression of the viral epidemic protecting the population. We further show that type III systems targeting jumbo phages have diverse accessory nucleases, including RNases that provide immunity. Our study demonstrates how type III CRISPR-Cas systems overcome the inaccessibility of jumbo phage DNA to provide robust immunity.
02 /Specification & Classification
Click any tag to browse matching papers- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A nucleus-forming jumbophage evades CRISPR-Cas DNA targeting but is vulnerable to type III RNA-based immunity
L. M. Malone, S. L. Warring, … P. C. Fineran·bioRxiv·Sep 25, 2019
- A nucleus-like compartment shields bacteriophage DNA from CRISPR-Cas and restriction nucleases
S. D. Mendoza, J. D. Berry, … J. Bondy-Denomy·bioRxiv·Jul 17, 2018
- A Type III-A CRISPR-Cas system employs degradosome nucleases to ensure robust immunity
L. Chou-Zheng, A. Hatoum-Aslan·bioRxiv·Feb 8, 2019
- Type I-F CRISPR-Cas resistance against virulent phage infection triggers abortive infection and provides population-level immunity
B. N. Watson, R. B. Vercoe, … P. C. Fineran·bioRxiv·Jun 21, 2019
- The Cas10 nuclease activity relieves host dormancy to facilitate spacer acquisition and retention during type III-A CRISPR immunity
Naama Aviram, Amanda K. Shilton, … Luciano A. Marraffini·Cell Host & MicrobePeer-reviewed·Dec 1, 2024
- Phage genome cleavage enables resuscitation from Cas13-induced bacterial dormancy
M. C. Williams, A. E. Reker, … A. J. Meeske·bioRxiv·Jul 5, 2022